Zoetis has announced the launch of Draxxin 25 (tulathromycin injection) Injectable Solution, a lower concentration of Draxxin (tulathromycin) Injectable Solution, to treat bovine respiratory disease (BRD) in suckling, dairy and veal calves.
The solution offers broad-spectrum coverage against the major causes of BRD, including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. However, producers and veterinarians should note that this product has a preslaughter withdrawal time of 22 days, compared with the 18-day preslaughter time for Draxxin.
“The new formulation of Draxxin 25 allows for more accurate and convenient dosing for smaller calves. Producers and veterinarians can be confident they are administering the correct treatment needed,” said Dr. Robert Lynch, senior veterinarian of the company’s dairy technical services.
Both products offer a convenient full course of therapy in a single dose. When administered according to the label, the solution is absorbed and distributed quickly to provide effective, single-dose therapy for BRD.
Draxxin 25 is available in 100 ml and 250 ml vials and may be purchased through your veterinarian or animal health retailer with a veterinarian’s prescription.
Draxxin label has also expanded for suckling and veal calves.
The company also announced the approval of Draxxin for the treatment against the major causes of BRD in suckling, dairy and veal calves. Previously, the product was approved only for use in nonlactating dairy cattle (cattle younger than 20 months of age, including dairy calves) and beef cattle.
Learn more about Draxxin 25 and the expanded label for Draxxin at Zoetis’ website. PD
—From Zoetis news release